Cargando…

The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy

Cancer immunotherapy has recently shown promising antitumor effects in various types of tumors. Among all immune checkpoints, the PD-1/PD-L1 pathway plays an important role in the immune evasion of tumor cells, making it a potent target in antitumor immunity. Accordingly, antibodies targeting the PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Wenxiao, Pan, Shuya, Chen, Xin, Wang, Zhi-wei, Zhu, Xueqiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424797/
https://www.ncbi.nlm.nih.gov/pubmed/34496886
http://dx.doi.org/10.1186/s12943-021-01406-7
_version_ 1783749731296477184
author Jiang, Wenxiao
Pan, Shuya
Chen, Xin
Wang, Zhi-wei
Zhu, Xueqiong
author_facet Jiang, Wenxiao
Pan, Shuya
Chen, Xin
Wang, Zhi-wei
Zhu, Xueqiong
author_sort Jiang, Wenxiao
collection PubMed
description Cancer immunotherapy has recently shown promising antitumor effects in various types of tumors. Among all immune checkpoints, the PD-1/PD-L1 pathway plays an important role in the immune evasion of tumor cells, making it a potent target in antitumor immunity. Accordingly, antibodies targeting the PD-1/PD-L1 pathway have been developed to attack tumor cells; however, resistance to immune therapy remains to be solved. Hence, identification of the underlying modulators of the PD-1/PD-L1 pathway is of significant importance to understand the mechanisms of antitumor immunotherapy. Long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) have been identified to regulate the PD-1/PD-L1 pathway, leading to participation in the immune response and immunotherapy. Therefore, this review focuses on the functions of lncRNAs and circRNAs in regulation of the PD-1/PD-L1 axis in tumorigenesis and tumor progression. We hope this review will stimulate research to supply more precise and effective cancer immune checkpoint therapies for a large number of tumors.
format Online
Article
Text
id pubmed-8424797
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84247972021-09-10 The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy Jiang, Wenxiao Pan, Shuya Chen, Xin Wang, Zhi-wei Zhu, Xueqiong Mol Cancer Review Cancer immunotherapy has recently shown promising antitumor effects in various types of tumors. Among all immune checkpoints, the PD-1/PD-L1 pathway plays an important role in the immune evasion of tumor cells, making it a potent target in antitumor immunity. Accordingly, antibodies targeting the PD-1/PD-L1 pathway have been developed to attack tumor cells; however, resistance to immune therapy remains to be solved. Hence, identification of the underlying modulators of the PD-1/PD-L1 pathway is of significant importance to understand the mechanisms of antitumor immunotherapy. Long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) have been identified to regulate the PD-1/PD-L1 pathway, leading to participation in the immune response and immunotherapy. Therefore, this review focuses on the functions of lncRNAs and circRNAs in regulation of the PD-1/PD-L1 axis in tumorigenesis and tumor progression. We hope this review will stimulate research to supply more precise and effective cancer immune checkpoint therapies for a large number of tumors. BioMed Central 2021-09-08 /pmc/articles/PMC8424797/ /pubmed/34496886 http://dx.doi.org/10.1186/s12943-021-01406-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Jiang, Wenxiao
Pan, Shuya
Chen, Xin
Wang, Zhi-wei
Zhu, Xueqiong
The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
title The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
title_full The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
title_fullStr The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
title_full_unstemmed The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
title_short The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
title_sort role of lncrnas and circrnas in the pd-1/pd-l1 pathway in cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424797/
https://www.ncbi.nlm.nih.gov/pubmed/34496886
http://dx.doi.org/10.1186/s12943-021-01406-7
work_keys_str_mv AT jiangwenxiao theroleoflncrnasandcircrnasinthepd1pdl1pathwayincancerimmunotherapy
AT panshuya theroleoflncrnasandcircrnasinthepd1pdl1pathwayincancerimmunotherapy
AT chenxin theroleoflncrnasandcircrnasinthepd1pdl1pathwayincancerimmunotherapy
AT wangzhiwei theroleoflncrnasandcircrnasinthepd1pdl1pathwayincancerimmunotherapy
AT zhuxueqiong theroleoflncrnasandcircrnasinthepd1pdl1pathwayincancerimmunotherapy
AT jiangwenxiao roleoflncrnasandcircrnasinthepd1pdl1pathwayincancerimmunotherapy
AT panshuya roleoflncrnasandcircrnasinthepd1pdl1pathwayincancerimmunotherapy
AT chenxin roleoflncrnasandcircrnasinthepd1pdl1pathwayincancerimmunotherapy
AT wangzhiwei roleoflncrnasandcircrnasinthepd1pdl1pathwayincancerimmunotherapy
AT zhuxueqiong roleoflncrnasandcircrnasinthepd1pdl1pathwayincancerimmunotherapy